関連する実験動画
Updated: Sep 10, 2025

13:22
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
8.0K
薬剤発見におけるALK5キナーゼ阻害剤:構造的洞察と治療的応用
Fang-Yan Guo1, Siqi Li1, Changhao Zhang1
1Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji, 133002, China.
European journal of medicinal chemistry
|August 27, 2025
まとめ
アクティブリン受容体型のキナーゼ5 (ALK5) 阻害剤は,TGF-β経路を標的として,癌および線維症の治療に有望である. 研究は臨床候補物質や化合物や 心臓毒性などの課題を 最適な治療法として強調しています
科学分野:
- 生化学と分子生物学
- 薬理学と薬剤発見
- 腫瘍学
背景:
- 成長因子-β (TGF-β) のシグナル伝達は,癌,炎症,および線維症において極めて重要です.
- アクティブリン受容体型のキナーゼ5 (ALK5) は,TGF-β経路の重要な媒介体である.
- ALK5を阻害剤で標的にすることは,様々な疾患の治療戦略を提供します.
研究 の 目的:
- ALK5 阻害剤の研究における最近の進歩をレビューする.
- 臨床用,合成用,天然の化合物に 集中する.
- 構造-活性関係 (SARs) と薬理学的プロファイルについて議論する.
主な方法:
- ALK5阻害剤に関する現在の文献の体系的なレビュー.
- 臨床試験データと臨床前試験の分析
- 薬物動力学 (PK) と薬物動力学 (PD) の評価
主要な成果:
- 抗腫瘍および抗線維性可能性を持つ有望なALK5阻害剤を特定した.
- 各種のALK5阻害剤のSARを要約した.
- 薬剤の有効性と安全性に影響を与えるPK/ PDプロファイルについて議論した.
結論:
- ALK5阻害剤は,がんおよび線維性疾患の有効な治療法です.
- SARとPK/PDを理解することは合理的な薬剤設計に不可欠です.
- 心臓の毒性などの問題に対処することは 臨床の成功に不可欠です
関連する概念動画
Drug Discovery: Overview
8.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.7K
M-Cdk Drives Transition Into Mitosis
5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Structure-Activity Relationships and Drug Design
1.0K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.0K
Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
Protein Kinases and Phosphatases
3.9K
3.9K

